论文部分内容阅读
目的:观察西艾克介入性治疗肝癌、肺癌的疗效及毒副反应。材料与方法:采用杭州民生制药厂生产的西艾克,分别与5-Fu、MMC、卡铂、Vp16组成不同的化疗方案,对30例不能手术的中晚期肝癌和肺癌进行动脉灌注化疗,其中原发性肝癌13例,转移性肝癌7例,原发性肺癌10例。全部病例均采用Seldinger 法将导管超选择插至肝总动脉和支气管动脉后,缓慢注入稀释的联合化疗药物。治疗前后均复查血象、肝功、肾功、CT 等以评价疗效及毒副反应。结果:以 CR+PR 为有效,原发性肝癌有效率为61.5%。转移性肝癌有效率为42.9%,原发性肺癌有效率为70%.总有效率60%。该药的骨髓抑制的毒副作用较大,70%病人有恶心、呕吐等消化道反应,脱发、指端麻木等毒副作用轻。结论:临床研究表明西艾克对肺癌有良好的疗效,但对肝癌的疗效一般,和其它的抗肝癌药物相比无显著差异。
OBJECTIVE: To observe the efficacy and side effects of the treatment of liver cancer and lung cancer by SCI. Materials and Methods: Xieike, produced by Hangzhou Minsheng Pharmaceutical Factory, was divided into 5-FU, MMC, carboplatin, and Vp16 different chemotherapy regimens. Arterial infusion chemotherapy was performed on 30 patients with inoperable advanced liver cancer and lung cancer. There were 13 cases of primary liver cancer, 7 cases of metastatic liver cancer, and 10 cases of primary lung cancer. In all cases, catheters were superselectively inserted into the common hepatic artery and bronchial artery using the Seldinger method, and the diluted combination chemotherapy drugs were slowly injected. Blood, liver function, renal function, and CT were reviewed before and after treatment to evaluate the efficacy and side effects. Results: With CR+PR as effective, the effective rate of primary liver cancer was 61.5%. The effective rate of metastatic liver cancer is 42.9%, and the effective rate of primary lung cancer is 70%. The total effective rate is 60%. The side effects of myelosuppression of the drug are relatively large, 70% of patients have nausea, vomiting and other gastrointestinal reactions, hair loss, finger numbness and other side effects are light. Conclusions: Clinical studies have shown that Sialk has a good effect on lung cancer, but its efficacy on liver cancer is general, and there is no significant difference compared with other anti-hepatoma drugs.